Literature DB >> 20519411

Equol: pharmacokinetics and biological actions.

Kenneth D R Setchell1, Carlo Clerici.   

Abstract

Equol [7-hydroxy-3-(4'-hydroxyphenyl)-chroman], an isoflavan produced by intestinal bacteria in response to soy isoflavone intake in some but not all humans, exhibits a wide range of biological properties. It exists as the diastereoisomers S-(-)equol and R-(+)equol. Intestinal bacteria produce exclusively S-(-)equol, which has selective affinity for estrogen receptor (ER)-beta. The evidence is conflicting on whether there is an advantage to producing S-(-)equol in response to soy isoflavone intakes, but the ability to now synthesize these diastereoisomers opens the way for future clinical trials to directly examine their potential in a number of hormone-dependent conditions. In this review, the plasma and urinary pharmacokinetics of S-(-)equol and R-(+)equol are reviewed and summarized, and some of the more recent evidence supporting potential biological effects of S-(-)equol is considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519411      PMCID: PMC2884334          DOI: 10.3945/jn.109.119784

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  90 in total

1.  Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women.

Authors:  Sanne Kreijkamp-Kaspers; Linda Kok; Michiel L Bots; Diederick E Grobbee; Johanna W Lampe; Yvonne T van der Schouw
Journal:  Am J Clin Nutr       Date:  2005-01       Impact factor: 7.045

2.  Interaction of phytoestrogens with estrogen receptors alpha and beta.

Authors:  K Morito; T Hirose; J Kinjo; T Hirakawa; M Okawa; T Nohara; S Ogawa; S Inoue; M Muramatsu; Y Masamune
Journal:  Biol Pharm Bull       Date:  2001-04       Impact factor: 2.233

3.  Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production.

Authors:  Wendy L Hall; Katerina Vafeiadou; Jesper Hallund; Susanne Bügel; Corinna Koebnick; Manja Reimann; Marika Ferrari; Francesco Branca; Duncan Talbot; Tony Dadd; Maria Nilsson; Karin Dahlman-Wright; Jan-Ake Gustafsson; Anne-Marie Minihane; Christine M Williams
Journal:  Am J Clin Nutr       Date:  2005-12       Impact factor: 7.045

4.  The vascular activity of some isoflavone metabolites: implications for a cardioprotective role.

Authors:  J P Chin-Dusting; L J Fisher; T V Lewis; A Piekarska; P J Nestel; A Husband
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

5.  Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback.

Authors:  Trent D Lund; Daniel J Munson; Megan E Haldy; Kenneth D R Setchell; Edwin D Lephart; Robert J Handa
Journal:  Biol Reprod       Date:  2003-12-17       Impact factor: 4.285

6.  The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers.

Authors:  Kenneth Dr Setchell; Xueheng Zhao; Pinky Jha; James E Heubi; Nadine M Brown
Journal:  Am J Clin Nutr       Date:  2009-08-26       Impact factor: 7.045

7.  Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials.

Authors:  De-Fu Ma; Li-Qiang Qin; Pei-Yu Wang; Ryohei Katoh
Journal:  Clin Nutr       Date:  2007-12-11       Impact factor: 7.324

8.  Effects of dietary equol administration on ovariectomy induced bone loss in Sprague-Dawley rats.

Authors:  Dominik Rachoń; Dana Seidlová-Wuttke; Tina Vortherms; Wolfgang Wuttke
Journal:  Maturitas       Date:  2007-10-24       Impact factor: 4.342

9.  Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents.

Authors:  Hideyuki Akaza; Naoto Miyanaga; Naomi Takashima; Seiji Naito; Yoshihiko Hirao; Taiji Tsukamoto; Tomoaki Fujioka; Mitsuru Mori; Wun-Jae Kim; Jae Mann Song; Allan J Pantuck
Journal:  Jpn J Clin Oncol       Date:  2004-02       Impact factor: 3.019

10.  Isoflavone effect on gene expression profile and biomarkers of inflammation.

Authors:  M Blay; A E Espinel; M A Delgado; I Baiges; C Bladé; L Arola; J Salvadó
Journal:  J Pharm Biomed Anal       Date:  2009-04-05       Impact factor: 3.935

View more
  62 in total

1.  Long-term soy isoflavone supplementation and cognition in women: a randomized, controlled trial.

Authors:  V W Henderson; J A St John; H N Hodis; N Kono; C A McCleary; A A Franke; W J Mack
Journal:  Neurology       Date:  2012-06-05       Impact factor: 9.910

2.  Epidemiological profiles between equol producers and nonproducers: a genomewide association study of the equol-producing phenotype.

Authors:  Kyung-Won Hong; Kwang-Pil Ko; Younjhin Ahn; Cheong-Sik Kim; Seon-Joo Park; Jae Kyung Park; Sung Soo Kim; Yeonjung Kim
Journal:  Genes Nutr       Date:  2012-04-03       Impact factor: 5.523

3.  Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk.

Authors:  Kenneth D R Setchell; Nadine M Brown; Xueheng Zhao; Stephanie L Lindley; James E Heubi; Eileen C King; Mark J Messina
Journal:  Am J Clin Nutr       Date:  2011-09-28       Impact factor: 7.045

4.  The effects of soy consumption before diagnosis on breast cancer survival: the Multiethnic Cohort Study.

Authors:  Shannon M Conroy; Gertraud Maskarinec; Song-Yi Park; Lynne R Wilkens; Brian E Henderson; Laurence N Kolonel
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

Review 5.  Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation.

Authors:  S Hüser; S Guth; H G Joost; S T Soukup; J Köhrle; L Kreienbrock; P Diel; D W Lachenmeier; G Eisenbrand; G Vollmer; U Nöthlings; D Marko; A Mally; T Grune; L Lehmann; P Steinberg; S E Kulling
Journal:  Arch Toxicol       Date:  2018-08-21       Impact factor: 5.153

6.  Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein.

Authors:  C L Frankenfeld; C Atkinson; K Wähälä; J W Lampe
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

Review 7.  The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?

Authors:  M Andrea Azcárate-Peril; Michael Sikes; José M Bruno-Bárcena
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-23       Impact factor: 4.052

8.  Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women.

Authors:  Gerson Hernandez; Liqin Zhao; Adrian A Franke; Yu-Ling Chen; Wendy J Mack; Roberta D Brinton; Lon S Schneider
Journal:  Menopause       Date:  2018-02       Impact factor: 2.953

9.  The soy isoflavone equol may increase cancer malignancy via up-regulation of eukaryotic protein synthesis initiation factor eIF4G.

Authors:  Columba de la Parra; Elisa Otero-Franqui; Michelle Martinez-Montemayor; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

10.  Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments.

Authors:  Jia Yao; Liqin Zhao; Zisu Mao; Shuhua Chen; Karren Carmen Wong; Jimmy To; Roberta Diaz Brinton
Journal:  Brain Res       Date:  2013-02-18       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.